A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Stopped early · Phase 1

Conditions studied: Cancer

In brief

The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.

Key facts

Study ID

NCT00326131

Run by

Bristol-Myers Squibb

People needed

6

Starts

2006-04-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non-hematological malignancy that has progressed on standard therapy
• No more that 3 prior chemotherapies given for advanced cancer
• Adequate renal, hepatic and hematologic function

You may not qualify if…

• Uncontrolled or significant pulmonary or cardiovascular disease
• Active Brain metastases
• Inability to swallow capsules
• Serious uncontrolled medical disorder or active infection

Where it is running

• Local Institution — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.